@LaughinPaulRyan Friday, 11/06/20 09:13:51 AM Re: None Post # of 52 The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Neuropathix conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA. For more information about Neuropathix, visit www.neuropathix.com and the Company’s Twitter page at @neuropathix. Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations: Kathryn Reinhardt Account Supervisor CMW Media P. 858-264-6600 E: firstname.lastname@example.org www.cmwmedia.com Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: email@example.com www.coreir.com @LaughinPaulRyan - WSJ, High Times, Main Street, Yahoo! Offering EXTREMELY valuable info and speculation without Explanation.